ArticleAnnals of hematology2025
Allogeneic stem cell transplantation with prior pembrolizumab and bendamustine therapy induce complete metabolic response in relapsed/refractory classical hodgkin lymphoma with relapse after nivolumab.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relapsed/refractory classical Hodgkin lymphoma (r/r cHL) poses a therapeutic challenge, particularly after failure of checkpoint inhibitors (CPIs) and brentuximab vedotin. We report a case of a heavily pretreated young male patient with r/r cHL who achieved complete metabolic response (CMR) after allogeneic hematopoietic stem cell transplantation (allo-HCT) following pembrolizumab and bendamustine therapy, currently in CMR at 19 months post-transplantation. Despite prior resistance to nivolumab, pembrolizumab combined with bendamustine contributed to disease control in the pre-transplant period. This case highlights allo-HCT's curative potential even in partial responders and suggests that pre-transplant CPI therapy may enhance the graft-versus-lymphoma effect, improving post-transplantation outcomes in r/r cHL. Another explanation for the therapeutic success may be that the employment of a CPI has likely contributed to sensitization to chemotherapy and bendamustine potentially lowering the occurrence of GvHD due to T-cell compartment impairment, with the need for large scale prospective trials to demonstrate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.